Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5

Yang Liu,Xiaojia Liu,Na Zhang,Mingxiao Yin,Jingwen Dong,Qingxuan Zeng,Genxiang Mao,Danqing Song,Lu Liu,Hongbin Deng
DOI: https://doi.org/10.1016/j.apsb.2020.06.014
IF: 14.903
2020-12-01
Acta Pharmaceutica Sinica B
Abstract:<p>Programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) blocking therapy has become a major pillar of cancer immunotherapy. Compared with antibodies targeting, small-molecule checkpoint inhibitors which have favorable pharmacokinetics are urgently needed. Here we identified berberine (BBR), a proven anti-inflammation drug, as a negative regulator of PD-L1 from a set of traditional Chinese medicine (TCM) chemical monomers. BBR enhanced the sensitivity of tumour cells to co-cultured T-cells by decreasing the level of PD-L1 in cancer cells. In addition, BBR exerted its antitumor effect in Lewis tumor xenograft mice through enhancing tumor-infiltrating T-cell immunity and attenuating the activation of immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs). BBR triggered PD-L1 degradation through ubiquitin (Ub)/proteasome-dependent pathway. Remarkably, BBR selectively bound to the glutamic acid 76 of constitutive photomorphogenic-9 signalosome 5 (CSN5) and inhibited PD-1/PD-L1 axis through its deubiquitination activity, resulting in ubiquitination and degradation of PD-L1. Our data reveals a previously unrecognized antitumor mechanism of BBR, suggesting BBR is small-molecule immune checkpoint inhibitor for cancer treatment.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem this paper attempts to address is: how to enhance anti-tumor immune response by suppressing the expression of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). Specifically, the researchers aim to find a small molecule drug that can effectively reduce the expression of PD-L1 on the surface of cancer cells, thereby improving T cell-mediated anti-tumor immune effects. ### Background - **Immune Evasion**: Various cancers, including non-small cell lung cancer (NSCLC), often evade immune surveillance by inhibiting the production of interferon-γ (IFN-γ), the proliferation of CD8+ T cells, or their cytolytic activity. - **Immune Checkpoint Blockade Therapy**: Antibody therapies targeting immune checkpoints (such as the PD-1/PD-L1 axis) have made significant progress in the treatment of NSCLC, but their efficacy is still limited to a subset of patients, with approximately 30% of patients experiencing relapse. - **Role of CSN5**: CSN5 is a multifunctional protein involved in the regulation of DNA repair, signal transduction, and cell proliferation. It regulates protein degradation through its deubiquitination activity and is crucial for cancer progression. ### Research Objectives - **Identify New PD-L1 Negative Regulators**: Researchers screened a group of traditional Chinese medicine monomers and identified an anti-inflammatory drug, Berberine (BBR), and validated its potential as a PD-L1 negative regulator. - **Mechanism Exploration**: Researchers further explored the specific mechanism by which BBR inhibits the deubiquitination activity of CSN5, leading to the ubiquitination and degradation of PD-L1. - **Anti-Tumor Effects**: Researchers evaluated the anti-tumor effects of BBR in both in vitro and in vivo experiments, particularly its ability to inhibit tumor growth by enhancing the immune response of tumor-infiltrating T cells. ### Main Findings - **BBR Reduces PD-L1 Expression**: BBR significantly reduces the protein level of PD-L1 in NSCLC cells without affecting the expression of other immune inhibitory ligands such as CD47 and B7-H3. - **BBR Enhances T Cell Killing Ability**: By reducing PD-L1 expression, BBR decreases the binding of cancer cells to PD-1, thereby restoring the anti-tumor activity of T cells. - **BBR Inhibits Tumor Growth**: In the Lewis lung cancer xenograft model, BBR significantly inhibited tumor growth, and this effect disappeared in T cell-deficient nude mice, indicating that BBR's anti-tumor effect is dependent on T cell immunity. - **BBR Alters Tumor Microenvironment**: BBR increased the number and activation of CD8+ T cells within the tumor while reducing the number of immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). ### Conclusion This study reveals a new mechanism by which Berberine (BBR) enhances anti-tumor immune response by inhibiting the deubiquitination activity of CSN5, thereby reducing PD-L1 expression. This finding provides a potential candidate drug for the development of new immune checkpoint inhibitors.